Skip to main content

Crispr Therapeutics Ag(CRSP-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low48.77
Day High55.18
Open:55.01
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy?
Motley Fool
2 Billion Reasons to Love CRISPR Therapeutics Right Now
Tipranks
Bank of America Securities Remains a Buy on Crispr Therapeutics AG (CRSP)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: CVS Health (CVS), Crispr Therapeutics AG (CRSP)
Motley Fool
This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area
Motley Fool
Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position?
Tipranks
Mizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
Trade The Pool
CRISPR Therapeutics: The Fundamental Standard-Bearer in a Fractured Genomic Sector
Medical research and development by Gorodenkoff via Shutterstock
Newswire.ca
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
Motley Fool
CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now?
Motley Fool
Is CRISPR Therapeutics Stock a Buy Now?
Tipranks
Crispr Therapeutics Completes $600 Million Convertible Notes Offering
Tipranks
Crispr Therapeutics Upsizes Convertible Notes Offering to $550 Million
Motley Fool
3 Monster Stocks to Hold for the Next 10 Years
Motley Fool
This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday
Motley Fool
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kyntra Bio (KYNB), Crispr Therapeutics AG (CRSP) and GoodRx Holdings (GDRX)
Motley Fool
Is CRISPR Therapeutics Stock Too Risky to Buy Right Now?
Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Newswire.ca
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
Motley Fool
Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?
Motley Fool
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices
Motley Fool
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street
MarketBeat
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
MarketBeat.com
Motley Fool
Should You Buy Shares of CRISPR Therapeutics in February?
Tipranks
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Galapagos (GLPG) and West Pharmaceutical Services (WST)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON)
Tipranks
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Organon (OGN)
Tipranks
Evercore ISI Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)
Tipranks
Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI
Tipranks
Analysts Conflicted on These Healthcare Names: Crispr Therapeutics AG (CRSP) and Bruker (BRKR)
Motley Fool
The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026

Profile

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.